Pacira reports preliminary Q3 2022 revenue of $167.5M, up 31% YoY; EXPAREL sales up 9%

Pacira BioSciences, Inc.

2022-Q3 EPS reported $0.56 revenue$494,868,000

Preliminary unaudited Q3 2022 revenue $167.5M vs $127.7M in Q3 2021.
EXPAREL net sales $132.6M (Q3 2022) vs $121.9M (Q3 2021); average daily sales 109% of prior year.
ZILRETTA net sales $26.5M for Q3 2022; iovera° net sales $4.5M.
Company not providing 2022 revenue or gross margin guidance due to macro uncertainty.
Monthly intra-quarter revenue disclosure continues; weekly EXPAREL utilization data posted on investor site.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.